Altamira Therapeutics Statistics
Total Valuation
CYTO has a market cap or net worth of $1.44 million. The enterprise value is $1.85 million.
Important Dates
The last earnings date was Tuesday, September 24, 2024, before market open.
| Earnings Date | Sep 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTO has 3.40 million shares outstanding. The number of shares has increased by 1,503.64% in one year.
| Current Share Class | 3.40M |
| Shares Outstanding | 3.40M |
| Shares Change (YoY) | +1,503.64% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.61% |
| Owned by Institutions (%) | 3.48% |
| Float | 3.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.43, with a Debt / Equity ratio of 0.07.
| Current Ratio | 0.43 |
| Quick Ratio | 0.15 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.80 |
Financial Efficiency
Return on equity (ROE) is -368.78% and return on invested capital (ROIC) is -99.80%.
| Return on Equity (ROE) | -368.78% |
| Return on Assets (ROA) | -57.15% |
| Return on Capital (ROIC) | -99.80% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$259,700 |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.25% in the last 52 weeks. The beta is 2.44, so CYTO's price volatility has been higher than the market average.
| Beta (5Y) | 2.44 |
| 52-Week Price Change | -94.25% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 34.45 |
| Average Volume (20 Days) | 104,390 |
Short Selling Information
The latest short interest is 31,093, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 31,093 |
| Short Previous Month | 11,575 |
| Short % of Shares Out | 0.91% |
| Short % of Float | 0.92% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.85M |
| Pretax Income | -4.47M |
| Net Income | -2.70M |
| EBITDA | n/a |
| EBIT | -6.85M |
| Earnings Per Share (EPS) | -$1.91 |
Full Income StatementBalance Sheet
The company has $65,455 in cash and $427,437 in debt, giving a net cash position of -$361,982 or -$0.11 per share.
| Cash & Cash Equivalents | 65,455 |
| Total Debt | 427,437 |
| Net Cash | -361,982 |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | 6.32M |
| Book Value Per Share | 2.37 |
| Working Capital | -703,852 |
Full Balance SheetCash Flow
| Operating Cash Flow | -7.58M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.58M |
| FCF Per Share | -$2.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |